GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (LTS:0HB0) » Definitions » Interest Expense (Positive)

Agios Pharmaceuticals (LTS:0HB0) Interest Expense (Positive)


View and export this data going back to 2018. Start your Free Trial

What is Agios Pharmaceuticals Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.


Agios Pharmaceuticals Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.